Assessment and Evolution of Narrative Identity and Its Relationship to Subjective Multidimensional Well-being and Multidimensional Recovery in First Episode Psychosis

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-30
SponsorCentre Hospitalier Universitaire de Nīmes

About this trial

First episode psychosis (FEP) constitutes an important subgroup within psychotic disorders, as the acute impact of a disorder at the time of diagnosis may differ from its long-term impact over the following decades. Narrative is identified as a sense of personal agency, of belonging to a social group, metacognition, and well-being. Patients with schizophrenia have lower levels of agency and communion compared to HIV-positive participants. However, the themes of agency and communion and metacognition do not reflect all factors representing narrative identity. In order to measure well-being, it is also necessary to introduce a specific and multidimensional measure that will allow a more precise understanding of the phenomenon.

In FEP, a link has been demonstrated between the specificity of self-recollection and functional outcomes. Given that the transitional developmental stage between adolescence and adulthood is a key developmental window for narrative identity as well as psychotic disorders and that narrative identity is positively associated with mental health, this study will therefore focus on the acquisition of narrative identity in the FEP. It will investigate the extent to which narrative identity has an impact on multidimensional subjective well-being and whether it can predict multidimensional subjective well-being over time. The study investigators hypothesize that the levels of the various components of narrative identity would be lower in cases of FEP compared to patients with other "chronic" psychotic conditions and controls.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subject who has given their free and informed consent.

Subject who has signed the consent form.

Subject who is a member of or beneficiary of a health insurance plan.

Presence of positive psychotic symptoms (delusions and/or hallucinations and/or conceptual disorganization) evolving for at least one week, either every day or at least 3 times a week for at least one hour per occasion

Disqualifiers

The subject is participating in category 1 RIPH or a clinical drug trial or clinical investigation study, or is in a period of exclusion determined by a previous study

The patient is unable to express consent

It is impossible to give the subject informed information

The patient is under safeguard of justice or state guardianship

Trial population

406 / 5,000 Three groups of participants will be formed: 1. a group of participants meeting the criteria for a FEP; 2. a group of "chronic" participants diagnosed with a psychotic disorder (recruited from patients at the Carémeau University Hospital in Nîmes); and 3. a control group of participants, representative of the general population (recruited through social media advertisements).

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Narrative identity task

    Other intervention

    Participants will be asked to elaborate five personal narratives in response to the different types of questions: trauma, transgression, negative memory, self-definition, and turning point.

Treatment groups

96 Participants
are divided into 3 treatment groups
Group A: First episode psychosis1 intervention
Group B: Chronic1 intervention
Group C: Control1 intervention

Trial outcomes

Primary outcomes

1

Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

Time frame
Baseline (Day 0)
2

Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

Time frame
Month 6
3

Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

Time frame
Month 12
4

Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

Time frame
Month 18

Secondary outcomes

1

Narrative identity between groups

PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

Time frame
Baseline (Day 0)
2

Narrative identity between groups

PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

Time frame
Month 6
3

Narrative identity between groups

PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

Time frame
Month 12
4

Narrative identity between groups

PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

Time frame
Month 18

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: